文献速递血栓与止血

222例重型血友病A伴抑制物>5 BU男童免疫耐受诱导前后出血的决定因素

Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU.
PubMed 文献 · Blood Adv · 2024-01-01

基于国际前瞻性PedNet队列,纳入222例抑制物>5 BU的重型血友病A患者,比较免疫耐受诱导(ITI)前后出血率与ITI方案及抑制物滴度的关联。ITI前115例年出血率(ABR)6.1(5.0-7.4)、年关节出血率(AJBR)2.6(2.1-3.2),出血与抑制物滴度无关;ITI期间202例ABR 4.4(3.9-5.1)、AJBR 1.7(1.5-2.0),AJBR随抑制物滴度升高而增加,每日ITI输注或活化凝血酶原复合物预防可降低AJBR。

要点

  • ITI前ABR 6.1(5.0-7.4)、AJBR 2.6(2.1-3.2),出血与抑制物滴度无关。
  • ITI期间ABR 4.4(3.9-5.1)、AJBR 1.7(1.5-2.0)。
  • ITI期间AJBR随抑制物滴度升高而增加,每日ITI输注或活化凝血酶原复合物预防可降低AJBR。

核心结论

  • 数据支持重复FVIII输注(ITI)对已产生抑制物患者出血具有保护作用。
  • 这些数据可用于规划ITI和/或作为非替代治疗预防的对照。

研究设计与样本

  • 国际前瞻性PedNet队列研究,选取抑制物>5 BU的重型血友病A患者。
  • 共222例患者,从首次抑制物阳性随访至首次阴性,中位总随访1.7年。
  • 采用多变量负二项回归比较年(关节)出血率及95%CI与治疗和抑制物滴度的关联。

主要发现

  • ITI前115例患者ABR为6.1(5.0-7.4),AJBR为2.6(2.1-3.2),出血与抑制物滴度无关。
  • ITI期间202例患者ABR为4.4(3.9-5.1),AJBR为1.7(1.5-2.0)。
  • ITI期间AJBR随抑制物滴度升高而增加:≥200 BU vs 5-39 BU的HR为4.9(95%CI 3.2-7.4)。
  • 每日ITI输注较非每日者AJBR降低:HR 0.4(95%CI 0.3-0.6);活化凝血酶原复合物预防较未预防者AJBR降低:HR 0.4(95%CI 0.2-0.8)。
  • ITI剂量和重组活化凝血因子VII预防未独立影响出血。

临床怎么用

  • 原文结论指出数据支持重复FVIII输注(ITI)对已产生抑制物患者出血具有保护作用。
  • 原文结论指出这些数据可用于规划ITI和/或作为非替代治疗预防的对照。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prevention of bleeding and its consequences is the main goal of hemophilia treatment and determines treatment choices for patients who develop inhibitors. To assess bleeding before and during immune tolerance induction (ITI) and its association with ITI regimen and inhibitor titer, we selected and analyzed data on patients receiving high-titer inhibitors from the international prospective PedNet cohort study. In total, 222 patients with severe hemophilia A and inhibitor titers of >5 Bethesda units (BU) were followed from the first positive to the first negative inhibitor result (median overall follow-up, 1.7 years). Mean annual (joint) bleeding rates (AJBR) and 95% confidence intervals (CIs) were compared according to treatment and inhibitor titer using multivariable negative binomial regression. Before ITI, 115 patients showed an ABR of 6.1 (5.0-7.4) and an AJBR 2.6 (2.1-3.2). Bleeding was independent of inhibitor titer. During ITI, 202 patients had an ABR of 4.4 (3.9-5.1) and an AJBR of 1.7 (1.5-2.0). AJBR during ITI increased with inhibitor titer (hazard ratio [HR] for ≥200 BU vs 5 to 39 BU [4.9; CI, 3.2-7.4]) and decreased with daily ITI infusions (HR, 0.4; CI, 0.3-0.6) or activated prothrombin complex concentrate prophylaxis (HR, 0.4; CI, 0.2-0.8), whereas ITI dose and recombinant activated factor VII prophylaxis did not independently affect bleeding. These data provide evidence for a protective effect of repeated FVIII infusions (ITI) on bleeding in patients who have developed inhibitors; these data should be used to plan ITI and/or serve as a comparator for prophylaxis with nonreplacement therapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Fischer K, Kenet G, Kurnik K, et al. Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU. Blood Adv. 2024. PMID: 38214949. doi:10.1182/bloodadvances.2023011442

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。